Showing results (31-40 of 70) with videos related to

Sort By:
Pageof 7
Cancers|April 3, 2021
Treatment of Angiosarcoma with Pazopanib and Paclitaxel: Results of the EVA (Evaluation of Votrient® in Angiosarcoma) Phase II Trial of the German Interdisciplinary Sarcoma Group (GISG-06)Daniel Pink, Dimosthenis Andreou, Sebastian Bauer, et al.
European Journal of Cancer Care|December 7, 2019
Does rehabilitation pose a risk to patients suffering from haemato-oncological diseases? Results of a monocentric, retrospective analysis in GermanyThomas Kiefer, Dorothea Krahl, Thomas Kohlmann, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|July 11, 2021
Financial toxicity in sarcoma patients and survivors in Germany: results from the multicenter PROSa studyMatthias Büttner, Susanne Singer, Leopold Hentschel, et al.
Cancers|February 10, 2024
Geriatric Assessment of Older Patients Receiving Trabectedin in First-Line Treatment for Advanced Soft Tissue Sarcomas: The E-TRAB Study from The German Interdisciplinary Sarcoma Group (GISG-13)Bernd Kasper, Daniel Pink, Christian Rothermundt, et al.
Journal of Cancer Research and Clinical Oncology|January 9, 2023
Working situation and burden of work limitations in sarcoma patients: results from the multi-center prospective PROSa studySergio Armando Zapata Bonilla, Marius Fried, Susanne Singer, et al.
Psycho-Oncology|August 11, 2022
Distress in soft-tissue sarcoma and gastrointestinal stromal tumours patients-Results of a German multicentre observational study (PROSa)Martin Eichler, Leopold Hentschel, Susanne Singer, et al.
European Journal of Cancer (Oxford, England : 1990)|February 24, 2022
FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel - results from the phase II RAMIRIS Study of the German Gastric Cancer Study Group at AIOSylvie Lorenzen, Peter Thuss-Patience, Claudia Pauligk, et al.
Oncology Research and Treatment|January 15, 2025
Preferences on Treatment Decision Making in Sarcoma Patients: Prevalence and Associated Factors - Results from the PROSa StudyHanna Salm, Markus K Schuler, Leopold Hentschel, et al.
JAMA Network Open|January 23, 2024
Ramucirumab, Avelumab, and Paclitaxel as Second-Line Treatment in Esophagogastric Adenocarcinoma: The Phase 2 RAP (AIO-STO-0218) Nonrandomized Controlled TrialPeter Thuss-Patience, Anica Högner, Eray Goekkurt, et al.
BMC Cancer|June 19, 2023
Ramucirumab plus irinotecan / leucovorin / 5-FU versus ramucirumab plus paclitaxel in patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed one prior line of palliative chemotherapy: the phase II/III RAMIRIS study (AIO-STO-0415)Sylvie Lorenzen, Alix Schwarz, Claudia Pauligk, et al.
Pageof 7